{"name":"Pacira BioSciences","slug":"pacira","ticker":"PCRX","exchange":"NASDAQ","domain":"pacira.com","description":"Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine","hq":"Tampa, FL","founded":0,"employees":"825","ceo":"Frank Lee","sector":"Pain Management / Non-Opioid","stockPrice":23.7,"stockChange":0.66,"stockChangePercent":2.86,"marketCap":"$933M","metrics":{"revenue":734864000,"revenueGrowth":5,"grossMargin":79.3,"rdSpend":117312000,"netIncome":7034000,"cash":202180000,"dividendYield":0,"peRatio":182.3,"fiscalYear":"FY2021"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"EXparel patent cliff ($1.3B at risk)","drug":"EXparel","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Pacira BioSciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Pacira BioSciences reported fourth quarter and full year 2023 financial results, with revenue of $133.8 million and a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Pacira BioSciences Announces Collaboration with Pfizer to Develop New Pain Management Therapies","summary":"Pacira BioSciences announced a collaboration with Pfizer to develop new pain management therapies, with a focus on non-opioid treatments.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves EXPAREL for Use in Pediatric Patients","summary":"The FDA approved EXPAREL for use in pediatric patients, expanding the product's indications and increasing its potential market.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-01","type":"pipeline","source":"simplywall.st","summary":"Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple - simplywall.st","headline":"Pacira BioSciences (PCRX) Valuation Check After Mixed Share Performance And High P/E Multiple","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K - PCRX - 12.31.2025","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOQ1J4c2ZjcGtWcHBpR0xLckljLWF3eFpDRVBQV3RDbUVIbjdCMXBZelQ3U2x3c0FPMmdrX1VueC1TUFNTbXZNbU4xdTBwaFptT3hGaHJoU1ktV1dWMWhmeC15T29UWXZPaEJFRGI0cTlic0tUbFZwYUZjM3Q5WkpNaEJiYTlTbHY3bEU1X2FTMEtELTNESFVXQlRrX0paWEJacU5RWUZ2ejBIVGo4M2FoVUxvTmNZRlhIRF9kTw?oc=5","date":"2026-02-03","type":"earnings","source":"TradingView","summary":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates - TradingView","headline":"5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-17","type":"earnings","source":"simplywall.st","summary":"Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive - simplywall.st","headline":"Revenues Working Against Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Share Price Following 28% Dive","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-12","type":"pipeline","source":"simplywall.st","summary":"Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist Pressure - Has The Bull Case Changed? - simplywall.st","headline":"Pacira BioSciences (PCRX) Is Down 6.3% After Cut 2025 Outlook And Activist Pressure - Has The Bull Case Changed?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQQVFSLTR4bC1NdVRGV2RQS1h3cHp4V0JOVWI2OFFDNVh4blFzNG1DZjVtWElsSmhrMXRMazF0NDNfRm85ZjluUEpxU1F1eWwzNEVLcEpoTUQtYzdOYTN1Q0RqNWhrcmd6ZmtVdDZyUnNlT0wzdzA1RE5lQWgzYUM5c1pjZE1vMzRoS0lNRVlIOE13RWU1U2c?oc=5","date":"2026-01-12","type":"earnings","source":"Finviz","summary":"PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates - Finviz","headline":"PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQc1pCYmlKZGtsNGM1SHFMblptbFNyd3lUU2JmaGNfUDh6NXMzQ3Bxc05tZTJ3aEFXbEN0VnoyYzY0aXI5Y2xpVkM0OWkwWVBrdWJNZDkzZ3l2d3lUNFR6UGR6SkVCQnFDaEZGZGdtQjN2TVBzektfRnFMWFdxMGVwaWxESHp3MHFOcW5aakt2SjFGS2oxU1B5bWN2VVl3eE5GcGJFVEJheUpwUWl1OVFURmJDZU5rU1lrVlE?oc=5","date":"2026-01-10","type":"pipeline","source":"Trefis","summary":"Pacira Stock (-9.6%): EXPAREL Decel Spooks the Street - Trefis","headline":"Pacira Stock (-9.6%): EXPAREL Decel Spooks the Street","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgJBVV95cUxNa29wNHlUcHhYNFZaa083Yy1UV09sak9VcWsyOV9Dd2xobHZkSFZPNWpsc2NGdFhESzZBcHlKaGNXLWw2b2hZX3pZcUswRUlydFJzTEMzeFdDUmRnUVNfMG5LM0t3MWo5TVRHQlVOMzE4UEZFb2RIbkV0VE5EWExmZG9haW15Zl90R0F5TzY5cVpkbWNxMkdNMF9tQ0N1NDNIQWgxc3d1UHJvOXhkajQtSHJoZFdXOXRsNFZjajZUaldWal9uQUdXb3FDZWNHVFY0Njlxa0ttLTVtYlc5SHBmUEZNX3h5NlVoTnRBbV95V0RPT2psMlZEYlVrdlRvRVBPejdmejJKQVQzVmlMOEtDNzhB?oc=5","date":"2025-11-26","type":"patent","source":"GlobeNewswire","summary":"Pacira BioSciences Files EXPAREL® Patent Infringement - GlobeNewswire","headline":"Pacira BioSciences Files EXPAREL® Patent Infringement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOdkFSbk5VbUdXQ21pWFJUTHdCUFVqNWVJUWhaV3k4ckFYV2pLYm4xc0gxcmp5eENBc1ZrWHJPQ0dHaGwxX2F4WkVTWGc3ZVJKdjRUR21sSzJxdlMxc21VUktWMkZXWllNMXR3OWEtd2ExQ3BCV245UW9nbUxqdTlnYUUyQjQ1OTRsT2pMdjh2Vmt2UkI4SlZmbEVINlVfWl9GcXhkcmpCRld2U0liVXVONkE5UnhfMlJKaXRBakloU3V5N2J5Q3c?oc=5","date":"2025-07-11","type":"pipeline","source":"Fierce Pharma","summary":"Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade - Fierce Pharma","headline":"Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTE1Rc0laY1FuSXVCVWFOczF6U0JnYk82RkdDYmtqNmdLSHJyX2NWNzZuWXVIVUdrZW1NSEhfSUNITFZXS1YwVlBTUHdvT1JTLXBiZG1ncTV5SQ?oc=5","date":"2025-07-07","type":"pipeline","source":"Stock Titan","summary":"PCRX SEC Filings - Pacira Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan","headline":"PCRX SEC Filings - Pacira Biosciences Inc 10-K, 10-Q, 8-K Forms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOLXJ3Z2I5QkRvUnh2ODNtbV9qaGRVc2hlTHRwZXJWc20zUVlwZ3NsTlJ1alRGbTVwR2dicFB5eU0wTjYwcVBKcmJyMGI1bkZSS041TVg5Q1lXeklFWnY1a1VTQ0VaTlBFeDNDOTRLNnR3OWdwcTdjXzVaODNPbVJiTk42QXdZQVluSGl1R1FDaGhwbG0wSzA2dFVUckVxU0JNNjdmZnNpdmh0NDY3LW9UMEljN0ZkeWpHUzNQcTlxOFNRbWNpN3UxUmtaNGM3YXQ1RWs2Qk1UenZlT2lJU1hwZXFtSnVPdGtOMURYeWhocFE3R3doc2hFNDF3?oc=5","date":"2025-05-13","type":"pipeline","source":"PR Newswire","summary":"Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation - PR Newswire","headline":"Lawsuit for Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) announced by the Shareholders Foundation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE85a0RYbXBYMWRfejB4UnlGT3hrMlB0NjFpUzUtdXlNbXF2MXczTVhPSU9PSjVFd1A0bE5WeE1na0dPY2NwRWUwRFRfZDdrUDh3eXFB?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"PCRX Stock Price, News & Analysis - Stock Titan","headline":"PCRX Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOYXJjeEg4d2lNeFF1c0F6bm03Y1EyVUozX0N2Y1owUFFUdGxfS0xXejRqUmZMbkZBdUFQTE82R2plQks4VXZOa1B1VXU5UVR5c3l0RVJoQ0xhal8zd2hHcVhBeUZicWpMRmlXV0Y5MUF3cm54cHVFRDRtamlQREREMDBFSVJlWHdUcmlsSzVpVW1GYjY4Vi0wak9Mc1NRMkVqRzVvOGptbjVfa0tLNVEzZVpkTQ?oc=5","date":"2025-04-09","type":"regulatory","source":"Seeking Alpha","summary":"Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act - Seeking Alpha","headline":"Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act","sentiment":"neutral"}],"patents":[{"drugName":"EXparel","drugSlug":"bupivacaine-liposome-injectable-suspension","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1300000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Johnson & Johnson","AbbVie","Merck & Co."],"therapeuticFocus":["Pain Management","Non-Opioid Therapies"],"financials":{"source":"sec_edgar+yahoo","revenue":541533000,"revenuePeriod":"2021-12-31","revenueHistory":[{"value":541533000,"period":"2021-12-31"},{"value":429647000,"period":"2020-12-31"},{"value":429647000,"period":"2020-12-31"},{"value":130974000,"period":"2020-12-31"},{"value":117484000,"period":"2020-09-30"}],"grossProfit":576662000,"grossProfitHistory":[{"period":"2025-12-31","value":576662000},{"period":"2024-12-31","value":530538000},{"period":"2023-12-31","value":490309000},{"period":"2022-12-31","value":467528000}],"rdSpend":117312000,"rdSpendHistory":[{"period":"2025-12-31","value":117312000},{"period":"2024-12-31","value":81577000},{"period":"2023-12-31","value":76257000},{"period":"2022-12-31","value":84797000}],"sgaSpend":368759000,"operatingIncome":19191000,"operatingIncomeHistory":[{"period":"2025-12-31","value":19191000},{"period":"2024-12-31","value":89872000},{"period":"2023-12-31","value":87675000},{"period":"2022-12-31","value":60024000}],"netIncome":7034000,"netIncomeHistory":[{"period":"2025-12-31","value":7034000},{"period":"2024-12-31","value":-99560000},{"period":"2023-12-31","value":41955000},{"period":"2022-12-31","value":15909000}],"eps":0.16,"epsHistory":[{"period":"2025-12-31","value":0.16},{"period":"2024-12-31","value":-2.15},{"period":"2023-12-31","value":0.89},{"period":"2022-12-31","value":0.34}],"cash":158545000,"cashHistory":[{"period":"2025-12-31","value":158545000},{"period":"2024-12-31","value":276774000},{"period":"2023-12-31","value":153298000},{"period":"2022-12-31","value":104139000}],"totalAssets":1264917000,"totalLiabilities":571806000,"totalDebt":418204000,"equity":693111000,"operatingCashflow":151994000,"operatingCashflowHistory":[{"period":"2025-12-31","value":151994000},{"period":"2024-12-31","value":189389000},{"period":"2023-12-31","value":154649000},{"period":"2022-12-31","value":145274000}],"capex":-15333000,"capexHistory":[{"period":"2025-12-31","value":-15333000},{"period":"2024-12-31","value":-10636000},{"period":"2023-12-31","value":-15161000},{"period":"2022-12-31","value":-30076000}],"freeCashflow":136661000,"dividendsPaid":null,"buybacks":-148328000,"employees":825,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":93944000,"ebit":8176000,"ebitda":29507000,"period":"2026-03-31","revenue":177376000,"epsBasic":0.07,"netIncome":2916000,"rdExpense":28072000,"epsDiluted":0.07,"grossProfit":140963000,"operatingIncome":4625000},{"sga":101608000,"ebit":3943000,"ebitda":25285000,"period":"2025-12-31","revenue":196873000,"epsBasic":0.04,"netIncome":1637000,"rdExpense":37453000,"epsDiluted":0.04,"grossProfit":156574000,"operatingIncome":-10921000},{"sga":91797000,"ebit":13177000,"ebitda":34368000,"period":"2025-09-30","revenue":179516000,"epsBasic":0.12,"netIncome":5432000,"rdExpense":25966000,"epsDiluted":0.12,"grossProfit":145238000,"operatingIncome":13153000},{"sga":88578000,"ebit":1919000,"ebitda":29241000,"period":"2025-06-30","revenue":181099000,"epsBasic":-0.11,"netIncome":-4847000,"rdExpense":28200000,"epsDiluted":-0.11,"grossProfit":140233000,"operatingIncome":9133000},{"sga":86776000,"ebit":12441000,"ebitda":33609000,"period":"2025-03-31","revenue":168923000,"epsBasic":0.1,"netIncome":4812000,"rdExpense":25342000,"epsDiluted":0.1,"grossProfit":134617000,"operatingIncome":8177000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":23.7,"previousClose":23.04,"fiftyTwoWeekHigh":27.64,"fiftyTwoWeekLow":18.8,"fiftyTwoWeekRange":"18.8 - 27.64","fiftyDayAverage":23.49,"twoHundredDayAverage":23.69,"beta":0.32,"enterpriseValue":1115575168,"forwardPE":6.6,"priceToBook":1.43,"priceToSales":1.27,"enterpriseToRevenue":1.52,"enterpriseToEbitda":9.2,"pegRatio":0,"ebitda":121288000,"ebitdaMargin":16.5,"freeCashflow":98615624,"operatingCashflow":142215008,"totalDebt":411179008,"debtToEquity":62.9,"currentRatio":4.73,"returnOnAssets":1.3,"returnOnEquity":0.7,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":7,"targetMeanPrice":29.29,"targetHighPrice":38,"targetLowPrice":23,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.7,"institutionHeldPercent":121.3,"sharesOutstanding":39347924,"floatShares":36390928,"sharesShort":7790589,"shortRatio":14.9,"shortPercentOfFloat":19.8,"epsTrailing":0.13,"epsForward":3.61,"revenuePerShare":17.05,"bookValue":16.63,"officers":[{"age":57,"name":"Mr. Frank D. Lee","title":"CEO & Director"},{"age":57,"name":"Mr. Shawn M. Cross","title":"Chief Financial Officer"},{"age":51,"name":"Ms. Kristen  Williams Esq., J.D.","title":"Chief Administrative Officer & Secretary"},{"age":50,"name":"Dr. Jonathan  Slonin M.D.","title":"Chief Medical Officer"},{"age":56,"name":"Mr. Brendan P. Teehan","title":"Chief Commercial Officer"},{"age":46,"name":"Ms. Lauren Bullaro Riker","title":"Principal Accounting Officer & Senior VP of Finance"},{"age":null,"name":"Ms. Susan  Mesco","title":"Head of Investor Relations"},{"age":51,"name":"Mr. Anthony  Molloy III, Esq.","title":"Chief Legal & Compliance Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.pacira.com","phone":"650 242 8052"}}